KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Notes Payables: 2009-2022

Historic Notes Payables for Novavax (NVAX) over the last 8 years, with Dec 2022 value amounting to $324.9 million.

  • Novavax's Notes Payables was N/A to $324.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $324.9 million, marking a year-over-year change of. This contributed to the annual value of $324.9 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Novavax reported Notes Payables of $324.9 million as of FY2022, which was up 82,148.35% from $395,000 recorded in FY2015.
  • Over the past 5 years, Novavax's Notes Payables peaked at $324.9 million during FY2022, and registered a low of $324.9 million during FY2022.
  • Moreover, its 1-year median value for Notes Payables was $324.9 million (2022), whereas its average is $324.9 million.